Abstract
The prescribing of isotretinoin in male patients has become a hot topic of debate in the UK following an independent report from the UK Commission on Human Medicines in October 2023. This has resulted in new safety guidance to encourage stricter monitoring of this cohort. We aimed to review patients in a tertiary hospital in the UK, where an online system has been monitoring genital side effects and mood for the past 3 years, prior to this change of guidance.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
